Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 2, 2005, Pages 182-188

  Posey, James A ^a   Wang, Hui ^b   Hamilton, JoElle ^c   Delgrosso, Alma ^c   Zhang, Ruiwen ^b   Freda, Timothy ^d   Zamboni, William C ^d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Docetaxel; Dose sequence; Phase I; Topotecan

Indexed keywords

ANTIBIOTIC AGENT; DOCETAXEL; PACLITAXEL; PROTEIN; SERUM ALBUMIN; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLADDER DISEASE; BLEEDING; BLOOD TOXICITY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG FATALITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LEUKOCYTE COUNT; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE ORGAN FAILURE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TAXOIDS; TOPOTECAN;

EID: 21244500884     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0925-8     Document Type: Article

References (20)

1. Boisdron-Celle M, Gamelin E (2000) Pharmacology of platinum analogs-taxanes interactions. Bull Cancer 87(Spec No):30-33
2. Clarke SJ, Rivory LP (1999) Related articles, links [abstract] clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99-114
3. D'Argenio DZ, Schmuitzky A (1990) ADAPT II user's guide: biomedical simulations resource
4. Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de Boeck G, de Bruijn E, Verweij J (2002) The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13(6):583-593
5. Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55(1):5-30
6. Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8(3):641-661
7. Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Related articles, links [abstract] comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121-129
8. Hong WK (2002) The current status of docetaxel in solid tumors. An M.D. Anderson Cancer Center Review. Oncology (Huntingt) 16(6 Suppl 6):9-15
9. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11(1):75-81
10. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88(11):734-741
11. Lilenbaum RC, List M, Desch C (1999) Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial. Semin Oncol 26(5 Suppl 15):52-54
12. Loos WJ, Verweij J, Nooter K et al (1997) Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 693:437
13. Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13-19
14. Philip PA (2002) Gemcitabine and platinum combinations in pancreatic cancer. Cancer 95(4 Suppl):908-911
15. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361(9376):2235-2242
16. Rosing H, Doyle E, Davites BE et al (1997) High-performance liquid chromatographic determination of the novel antitumor drug topotecan and topotecan as the total of the lactone plus carboxylate forms in human plasma. J Chromatogr Biol Biomed Appl 668:107
17. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Related articles, links [abstract] superiority of oxaliplatin and fluorouracil- leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059-2069
18. Sederholm C (2002) Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 3(Suppl 9):50-54
19. Ulukan H, Swaan PW (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62(14):2039-2057
20. Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH (2000) Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 18(18):3288-3294